With a market capitalization (market cap) of $3.07B — a measure of how much the company is worth — Alumis Inc. is the 1798th most valuable company in Healthcare as of August 18, 2026. Shares trade at $24.88, down +2.43% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Visit websiteAs of August 18, 2026, Alumis Inc. (ALMS) is worth $3.07B — this is its market capitalization, the total value of all its outstanding shares.
Alumis Inc.’s market cap is $3.07B, which ranks it #1798 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Alumis Inc. (ALMS) shares trade at $24.88, down 2.43% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025